arGenX (argenx)
↗Amsterdam, Netherlands
arGenX (argenx SE) is a commercial-stage biopharmaceutical company headquartered in Amsterdam, Netherlands, focused on developing human antibody therapeutics for autoimmune diseases and other severe conditions. The company specializes in immunology innovation with a platform technology called NHance and a simple antibody technology (ABDEG) platform. arGenX has successfully commercialized VYVGART (efgartigimod alfa and hyaluronidase-qvfc), a neonatal Fc receptor (FcRn) blocker, which addresses multiple autoimmune indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company's strategy is outlined in their 'Vision 2030' initiative, targeting to bring breakthrough science to 50,000 patients globally.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Biopharmaceuticals - Immunology
SIZE & FINANCIALS
Employees:1001-5000
Revenue:$2.2B (preliminary full-year 2024)
Founded:2008
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:Omnes Capital, EQT Life Sciences, BioGeneration Ventures, Erasmus MC Biomedical Fund, Forbion, Thuja Capital, KBC Private Equity, Seventure, OrbiMed Advisors
STOCK
Exchange:NASDAQ
Ticker:ARGX
Market Cap:$52.3B
PIPELINE
Stage:Phase 1 through Commercial
Lead Drug Stage:Commercial (VYVGART approved)
Modalities:Monoclonal Antibodies, Antibody Fragments, FcRn Antagonists
Active Trials:50
Trial Phases:Phase 1: 4 | Phase 2: 10 | Phase 3: 10
FDA Approvals:2
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:arGEN-X B.V. (Netherlands subsidiary)
Key Partnerships:Halozyme: ENHANZE technology partnership for drug delivery, FUJIFILM Biotechnologies: Manufacturing and CDMO partnership for VYVGART production in Denmark (Hillerød) and planned U.S. expansion (Holly Springs, NC), LEO Pharma: Exclusive worldwide license for ARGX-112 development and commercialization, Unnatural Products: Collaboration for macrocyclic peptide therapeutics, OncoVerity: Co-development partnership for cusatuzumab in oncology
COMPETITION
Position:Leader
Competitors:Ultragenyx Pharmaceutical (UCB) - RYSTIGGO, ZILBRYSQ, Johnson & Johnson - IMAAVY (nipocalimab), AstraZeneca - Soliris, Amgen, Regeneron
LEADERSHIP
Key Executives:
Tim Van Hauwermeiren - Chief Executive Officer & Co-founder
Karen Massey - Chief Operating Officer
Karl Gubitz - Chief Financial Officer
Achim Plueckebaum - Global Head of Digital, Data, and IT
Scientific Founders:Tim Van Hauwermeiren (Co-founder, CEO)
Board Members:Tim Van Hauwermeiren (Executive Director & CEO), Brian Kotzin (Non-Executive Director & R&D Committee Chair), Peter Verhaeghe (Non-Executive Director), Steve Krognes (Non-Executive Director & Audit Committee Chair), Donald deBethizy (Non-Executive Director), Anthony Rosenberg (Non-Executive Director), Pamela Klein (Non-Executive Director)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with arGenX (argenx). The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.